Vaxys President News Today : Breaking News, Live Updates & Top Stories | Vimarsana

BioVaxys Announces Allowance of DPX Formulation Patent for the United States and Filing of Additional International Patent Applications for Phase 1 DPX SurMAGE

/PRNewswire/ BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced that it has received a Notice of Allowance.

United kingdomBritish columbiaUnited statesKenneth kovanSanofi pasteur fluzoneImv incPrnewswire biovaxys technology corpEuropean unionBiovaxys or companyTrademark officeBiovaxys technology corpVaxys technologyUnited states patentIntellectual propertyIntradermal quadrivalentWhereast cells

BioVaxys Technology Corp : BioVaxys and Procare Health Agree to Termination of USA Distribution Agreement for Papilocare

BioVaxys Technology Corp : BioVaxys and Procare Health Agree to Termination of USA Distribution Agreement for Papilocare
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

British columbiaUnited statesStefan klotterKenneth kovanPrnewswire biovaxys technology corpBiovaxys or companyProcare healthBiovaxys technology corpVaxys technologyVaxys presidentChief operating officer kenneth kovanFrankfurt bourseLassen sie

BioVaxys and Procare Health Agree to Termination of USA Distribution Agreement for Papilocare

VANCOUVER, BC, Dec. 21, 2023 /PRNewswire/ BioVaxys Technology Corp. announced today that as part of BioVaxys efforts to refocus on immunotherapeutics, Biovaxys and Procare Health have.

United statesBritish columbiaKenneth kovanPrnewswire biovaxys technology corpBiovaxys technology corpProcare healthBiovaxys or companyVaxys technologyVaxys presidentChief operating officer kenneth kovanFrankfurt bourse

BioVaxys Announces Successful Test-Run Production of its Bi-Haptenized Ovarian Cancer Vaccine

VANCOUVER, BC, Dec. 1, 2022 /PRNewswire/ BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ('BioVaxys' or 'Company') is pleased to

United statesUnited kingdomBritish columbiaKenneth kovanBiovaxys technology corpProcare health iberiaBiovaxys or companyPrnewswire biovaxys technology corpJba inc davinVaxys technologyNew drugVaxys presidentChief operating officer kenneth kovanBiovaxys technologyBritish columbia registeredFrankfurt bourse

Research and Development of Advanced Therapeutics for Ovarian Cancer Fueling Hope

/PRNewswire/ The global ovarian cancer market is projected to continue to grow through the coming several years. The formation of mutational cells or.

United statesMegan omearaAdam craigKenneth kovanBiovaxys technologyFn media groupBiopharma corpBiovaxys technology corpProcare health iberiaHaptenized ovarian cancer biovaxys technology corpStage development at seagenImmunogen incSociety for immunotherapy of cancerDrug administrationData monitoring committeeSeagen inc